Marshall Wace
NVO

Marshall Wace’s Novo Nordisk NVO Stock Holding History

Marshall Wace’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-130,000
Closed -$8.97M – 3246
2025
Q2 		$8.97M Buy
+130,000
New +$8.84M 0.01% 886

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Marshall Wace's NVO Position: Q2 2026 in Review

Marshall Wace reduced its Novo Nordisk (NVO) stake by 44% in Q2 2026, selling an estimated $57.6M and leaving 1,707,104 shares worth $81.8M. The position accounts for 0.06% of the portfolio, ranked #244.

Marshall Wace first reported a position in NVO in Q3 2015 and has held it in 22 quarters since. The position peaked at $112M in Q1 2026. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Marshall Wace held 1,707,104 shares of Novo Nordisk worth $81.8M as of Q2 2026.
  • Marshall Wace sold 1,339,507 Novo Nordisk shares in Q2 2026, an estimated $57.6M.
  • Novo Nordisk made up 0.06% of Marshall Wace's portfolio in Q2 2026, its #244 holding.
  • Marshall Wace first reported a position in Novo Nordisk in Q3 2015 and has held it in 22 quarters since.
  • Marshall Wace's Novo Nordisk position peaked at $112M in Q1 2026.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.